19 reports

  • A cohort study of 868 IMD survivors in Canada between 2002-2011
  • 3.1 BIBLIOGRAPHY

Meningococcal disease.

  • Laboratory
  • Meningococcal
  • Brazil
  • United States
  • Forecast
  • MENINGOCOCCAL [SEROTYPE B] VACCINE - DRUG PROFILE
  • MENINGOCOCCAL [SEROTYPE B] VACCINE - DRUG PROFILE

Neisseria meningitidis Infections - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2018, provides an overview of the Neisseria meningitidis Infections (Infectious Disease)...

  • Meningococcal
  • China
  • United States
  • World
  • Product Initiative
  • MENINGOCOCCAL (TETRAVALENT) VACCINE - DRUG PROFILE
  • MENINGOCOCCAL [STRAIN C2135] VACCINE - DRUG PROFILE

Neisseria meningitidis Infections - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H1 2018, provides an overview of the Neisseria meningitidis Infections (Infectious Disease)...

  • Meningococcal
  • China
  • United States
  • World
  • Product Initiative
  • MENINGOCOCCAL [SEROTYPES A, C] VACCINE - DRUG PROFILE
  • MENINGOCOCCAL [SEROTYPES A, C] VACCINE - DRUG PROFILE

Meningitis - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H1 2018, provides an overview of the Meningitis (Infectious Disease) pipeline landscape. "Meningitis is the inflammation caused by...

  • Infectious Disease
  • Meningococcal
  • Therapy
  • United States
  • Product Initiative
  • SYMPTOMS OF MENINGOCOCCAL DISEASE
  • 5.1 MENINGOCOCCAL IMMUNIZATION POLICY

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025 Summary Neisseria meningitidis is a Gram-negative, encapsulated diplococcal bacterium and is the causative agent for invasive meningococcal disease. Although relatively rare around the globe, invasive meningococcal disease is widely...

  • Meningococcal
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • MENINGOCOCCAL [SEROTYPES A, C] VACCINE - DRUG PROFILE
  • Meningitis - Drug Profiles

Meningitis - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H2 2017, provides an overview of the Meningitis (Infectious Disease) pipeline landscape. "Meningitis is the inflammation caused by...

  • Meningococcal
  • Pharmaceutical
  • United States
  • Product Initiative
  • ContraFect Corporation
  • MENINGOCOCCAL [SEROTYPE B] VACCINE ALONE OR IN COMBINATION HAS THE HIGHEST NUMBER OF NEISSERIA MENINGITIDIS INFECTIONS ONGOING CLINICAL TRIALS.
  • Clinical Trial profile. 5 Trial Title

Neisseria meningitidis Infections Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Neisseria meningitidis Infections Global Clinical Trials Review, H1, 2018" provides an overview of Neisseria meningitidis Infections clinical trials scenario.This report provides...

  • Infectious Disease
  • Meningococcal
  • Vaccine
  • World
  • GlaxoSmithKline plc
  • CAUSES OF MENINGOCOCCAL DISEASES
  • Introduction

About Meningitis Meningitis (meningococcal diseases) is characterized by inflammation of the protective lining (meninges) present around the brain and spinal cord. It can be classified into infectious and non-infectious meningitis. Based on the types of organism, infectious meningitis is sub-divided into bacterial meningitis, viral...

  • Meningococcal
  • Market Size
  • Meningococcal group
  • Pfizer Inc.
  • Sanofi S.A.
  • Target Company Information Company Name
  • Target Company Information Company Name

Summary Walvax Biotechnology Co Ltd (Walvax) is a biopharmaceutical company that develops, produces and markets bio-medical products including vaccines and blood products.The company’s products include haemophilus influenzae vaccine for the prevention of infectious diseases such as meningitis. Walvax offers drugs...

  • Biotechnology
  • Meningococcal
  • Monoclonal Antibody
  • China
  • Walvax Biotechnology Co., Ltd
  • Clinical Trial profile. 151 Trial Title
  • Clinical Trial profile. 251 Trial Title

Meningitis Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Meningitis Global Clinical Trials Review, H2, 2017" provides an overview of Meningitis clinical trials scenario. This report provides top line data relating to the clinical trials on Meningitis. Report...

  • Clinical Trial
  • Meningococcal
  • Therapy
  • World
  • Sanofi S.A.

DISEASE OVERVIEW Meningococcal infection is one of the serious and death causing infections worldwide.

  • Meningococcal
  • Pathology
  • World
  • Key marketed vaccines for meningococcal disease
  • KEY MARKETED VACCINES FOR MENINGOCOCCAL DISEASE

The recent inclusion of premium-priced meningococcal B (MenB) vaccines into the routine immunization schedules of the US, Italy, and the UK is set to drive strong market growth, which will be further boosted by the anticipated launch of GlaxoSmithKline’s pentavalent MenABCW-135Y vaccine from 2021. This report addresses the following...

  • Meningococcal
  • United States
  • GlaxoSmithKline plc
  • Meningococcal group
  • Pfizer Inc.

## ## ## United Kingdom ## ## ## ## ## France ## ## ## ## ## Germany ## ## ## ## ## Italy ## ## ## ## ## Japan ## ## ## ## ## Canada Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials

  • Infectious Disease
  • Meningococcal
  • World
  • Product Initiative
  • Pfizer Inc.
  • BACTERIAL (PYOGENIC) MENINGITIS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017*
  • Clinical Trial profile. 34

Bacterial (Pyogenic) Meningitis Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Bacterial (Pyogenic) Meningitis Global Clinical Trials Review, H1, 2017" provides an overview of Bacterial (Pyogenic) Meningitis clinical trials scenario. This report provides top line data relating to the...

  • Infectious Disease
  • Meningococcal
  • World
  • Product Initiative
  • Pfizer Inc.
  • MONO VACCINES
  • MARKET OVERVIEW

About Travel Vaccines As the world continues to move toward globalization, the international travels will keep increasing. This fuels the demand for travel vaccines as the prevalence of infectious diseases are specifically region prone, unlike that of other indications. As vaccines are largely used as a preventive measure against these...

  • Meningococcal
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • APR 24, 2018: HIBERGENE DIAGNOSTICS LAUNCHES NEW RAPID TEST FOR BACTERIAL MENINGITIS
  • HIBERGENE DIAGNOSTICS ENTERS INTO LICENSING AGREEMENT WITH EIKEN FOR LAMP

GlobalData HiberGene Diagnostics Ltd, reported one medical equipment deal each in 2016 and 2017.

  • Diagnostics
  • Meningococcal
  • Ireland
  • Deals & Alliance
  • Hibergene Diagnostics Limited
  • Clinical Trial profile. 142 Trial Title
  • Clinical Trial profile. 37 Trial Title

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2015" provides an overview of Neisseria meningitidis Infections clinical trials scenario. This report provides top line data relating...

  • Infectious Disease
  • Meningococcal
  • Vaccine
  • World
  • Product Initiative
  • Pneumococcal Meningitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

Pneumococcal Meningitis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Pneumococcal Meningitis Global Clinical Trials Review, H2, 2016" provides an overview of Pneumococcal Meningitis clinical trials scenario. This report provides top line data relating to the clinical trials on Pneumococcal...

  • Infectious Disease
  • Meningococcal
  • Vaccine
  • World
  • Product Initiative
  • MENINGOCOCCAL [SEROTYPE B] VACCINE
  • INVASIVE MENINGOCOCCAL DISEASE DUE TO NEISSERIA MENINGITIDIS SEROGROUP B IN PERSONS 10 - 25 YEARS OF AGE.

Pfizer Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Pfizer Inc. - Product Pipeline Review - 2016’, provides an overview of the Pfizer Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Pfizer Inc.,...

  • Lymphoma
  • Meningococcal
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.